Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Intravenous antihypertensive agents for the treatment of hypertensive emergencies are reviewed ... Nicardipine 5-mg/hr infusion, increase dosage by 2.5 mg/hr every 5–15 minutes to a maximum ...